News

NS2 is an aldehyde-binding small molecule based on a platform technology that centers on trapping aldehydes, which are toxic and pro-inflammatory mediators of several diseases. It lowers aldehyde

Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam. Menarini

A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the 100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS)

Published in the February 2016 edition of Clinical Trials: Journal of the Society for Clinical Trials, the analysis identifies different factors, such as therapeutic area, patient recruitment, administrative

About 85 percent of NHL is of B-cell lineage, and CD19 is broadly expressed across all subtypes of B-cell malignancies. SGN-CD19B is a novel antibody-drug conjugate (ADC) targeted

TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread® 245 mg of tenofovir disoproxil (as fumarate) (TDF) at one-tenth

Growing evidence has suggested high levels of intense exercise may actually damage your heart causing permanent structural changes resulting in an abnormal heart rhythm. A review published in

Precision BioSciences’ ARCUS genome editing technology will be used to develop an allogeneic chimeric antigen receptor (CAR T) cell therapeutic pipeline directed towards areas of major unmet need

Last December, AstraZeneca agreed to acquire a 55% stake in privately-owned biotech firm Acerta Pharma for $4bn. Acalabrutinib has been recommended as an orphan product for chronic lymphocytic